Medicaid Coverage of GLP-1s by State

Medicaid is not one program. It is 51 programs — 50 states plus the District of Columbia — that share federal rules but make their own choices in the places that matter most for these drugs. Two people with the same diagnosis, the same BMI and the same Medicaid card can get completely different answers depending on which side of a state line they live on.

This article explains where the line falls, what is required everywhere regardless of state politics, what has changed recently, and how to check your own state. It is not medical advice. Where it describes how a medicine is used, it is summarizing FDA-approved labeling and Instructions for Use; follow your own prescription and your prescriber’s directions.

Why is this optional at all?

Under the Medicaid Drug Rebate Program, state Medicaid programs must cover nearly all FDA-approved drugs from participating manufacturers for medically accepted indications. But federal law carves out a short list of categories that states may exclude, and drugs used for “weight loss” are on that list [1].

That single statutory exception is the whole story. It is why coverage for a GLP-1 prescribed for type 2 diabetes is mandatory in every state, and coverage for the same molecule prescribed for obesity is a state budget decision.

What must every state Medicaid program cover?

Regardless of a state’s position on obesity drugs, coverage is required for GLP-1s approved to treat:

• Type 2 diabetes — this has always been required.
• Cardiovascular risk reduction — required since Wegovy’s March 2024 approval for reducing major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight [1].
• Moderate-to-severe obstructive sleep apnea in adults with obesity — required since Zepbound’s December 2024 approval for that indication [1].

Coverage is also required when medically necessary for people under 21 under Medicaid’s Early and Periodic Screening, Diagnostic and Treatment (EPSDT) benefit, even in states that exclude adult obesity drug coverage [1].

North Carolina’s 2025 announcement shows how this works in practice. When NC Medicaid stopped covering GLP-1s for weight management, it stated plainly that coverage continued for diabetes, for reduction in cardiovascular death, heart attack and stroke in adults with obesity and cardiovascular disease, for noncirrhotic MASH, and for severe obstructive sleep apnea [3].

Whether one of those indications applies to you is a clinical question for your provider, not something to select from a menu.

Which states cover GLP-1s for obesity?

KFF’s January 2026 analysis found 13 state Medicaid programs covering GLP-1s for obesity treatment under fee-for-service [1]:

Delaware, Kansas, Massachusetts, Michigan, Minnesota, Missouri, Mississippi, North Carolina, Rhode Island, Tennessee, Utah, Virginia and Wisconsin.

One of those 13 has since dropped out. MassHealth published Pharmacy Facts #271 on March 12, 2026 stating that, in line with anticipated changes to 130 CMR 406.413(B), it would no longer cover drugs used for the treatment of obesity or overweight — naming Wegovy, Zepbound, Saxenda, Xenical, phentermine and the older appetite suppressants — effective July 3, 2026 [13]. The change went into effect on schedule and was reported to affect roughly 22,000 members [14]. GLP-1s remain covered for MassHealth members with another medically accepted indication, but a new prior authorization is required. That leaves 12 states covering GLP-1s for obesity as of September 2026, on KFF’s January list adjusted for Massachusetts. KFF has not reissued its count, so treat the 12 as this guide’s arithmetic rather than KFF’s published figure. A second state is dropping out on October 1, 2026: Rhode Island eliminates Medicaid coverage of GLP-1s prescribed for weight loss or weight management on that date, taking the working count to 11 [17][18]. Rhode Island should be read as a dropping state, not a covering one, from October 1. Any undated state list of this kind goes out of date within weeks. (updated 2026-09-14)

Two footnotes matter. KFF flags that Utah reported funding for coverage was limited to fiscal year 2026. And seven states — Connecticut, Louisiana, New Hampshire, New Mexico, North Dakota, Pennsylvania and Texas — reported covering one or more weight-loss drugs but no GLP-1s [1]. That is the difference between “covers a weight-loss drug” and “covers Wegovy or Zepbound,” and it trips up a lot of searches.

This is a January 2026 snapshot. State Medicaid coverage moves with state budgets, sometimes mid-year. Always verify against your state’s current preferred drug list.

What changed in 2025 and 2026?

The direction of travel has reversed. KFF’s 2025 Medicaid budget survey, conducted with Health Management Associates in November 2025, found 16 states covering GLP-1s for obesity as of October 2025. Since then [1]:

• California, New Hampshire, Pennsylvania and South Carolina eliminated coverage, effective January 1, 2026. Reporting attributes the cuts to state budget pressure. California’s spending on these drugs had reportedly quadrupled in 18 months; Pennsylvania ended coverage for adults 21 and over while preserving under-21 access through EPSDT.
• North Carolina eliminated coverage beginning October 2025 during a legislative budget stalemate, then reinstated it in December 2025 [1][3].
• Massachusetts ended coverage of drugs used only for obesity or overweight effective July 3, 2026, after KFF’s snapshot was published [13][14].

Net effect: 16 in October 2025, 13 in January 2026, and 12 from July 2026. KFF also reports that state interest in expanding obesity drug coverage is waning, with cost cited as the key factor in coverage decisions, and that a few other states were planning or considering restrictions in state fiscal year 2026 or 2027 [1].

Stateline reported in April 2026 that more states were weighing dropping the benefit, and noted that state employee health plans are reassessing separately from Medicaid [2][11].

How much is Medicaid actually spending?

The numbers explain the politics. KFF’s analysis of State Drug Utilization Data found that between 2019 and 2024 [1]:

• Medicaid GLP-1 prescriptions rose sevenfold, from about 1 million to over 8 million.
• Gross Medicaid spending on GLP-1s rose ninefold, from about $1 billion in 2019 to almost $9 billion in 2024 (verified 2026-09-14).
• Gross spending per GLP-1 prescription reached $1,000 in 2024. These are gross program figures before rebates — states typically receive substantial rebates on brand drugs — and they are not what any individual pays.
• GLP-1s were about 1 percent of all Medicaid prescriptions but over 8 percent of all Medicaid prescription drug spending before rebates, up from 1 percent in 2019.

Those are gross figures before rebates, and states typically receive substantial rebates on brand drugs. Novo Nordisk has reported that rebates and other fees across all payers accounted for about 40 percent of the cost of Ozempic and Wegovy [1]. Publicly available Medicaid data cannot separate how much of the growth is obesity versus diabetes, cardiovascular disease or sleep apnea [1].

What restrictions apply where coverage exists?

Coverage is not the same as easy access. KFF notes that when covered, GLP-1s are typically subject to utilization controls such as prior authorization, which further limit access [1]. Common requirements mirror the commercial market: BMI thresholds, documented comorbidities, participation in a weight-management program, and quantity limits.

California’s Medi-Cal pharmacy program, for instance, restricts Wegovy and Saxenda to a maximum of one carton per dispensing and one dispensing every 28 days — one carton being four single-dose Wegovy pens or five Saxenda pens [10].

What is the BALANCE model, and will it change anything?

In December 2025 the Trump administration introduced BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth), a five-year CMS Innovation Center model intended to expand access to obesity drugs in Medicaid and Medicare by negotiating lower GLP-1 prices, with standardized coverage criteria and lifestyle supports built in [1][5].

Key points for a Medicaid enrollee:

• It is voluntary for state Medicaid programs, Medicare Part D plans and manufacturers. A state has to opt in.
• States and manufacturers were asked to submit intentions to participate by January 8, 2026, with the model expected to begin in May 2026 [1].
• For Medicare Part D, implementation was planned for January 2027 but has been delayed, which is why CMS extended the separate Medicare GLP-1 Bridge demonstration through December 31, 2027 [5].
• The state uptake is now close to a null result. The state Medicaid application window runs to January 1, 2027, with a July 31, 2026 notice deadline. As of early September 2026 only Indiana had publicly committed to participate, 29 state Medicaid programs had declined — citing cost, budget constraints and doubts about long-term sustainability — and the CMS BALANCE model page still lists the number of participants as “not applicable” [15][16]. Read the section below as a description of what the model was designed to do, not of what it has done. (updated 2026-09-14)

KFF’s caution is worth repeating: lower prices for state Medicaid programs could ease cost concerns and lead to expanded coverage, but how the new lower prices compare to the net prices states already pay after rebates is unclear, and states are contending with tighter budgets [1]. KFF also notes that the recent price announcements will not change costs for Medicaid enrollees themselves, since they already pay little or nothing for prescriptions, and that buying directly through a manufacturer website will likely remain prohibitive for people with Medicaid-level incomes [1].

How does this compare with ACA Marketplace coverage?

If you are choosing between Medicaid and a Marketplace plan, or losing Medicaid eligibility, the Marketplace is not a reliable upgrade for these drugs.

An analysis by Leverage|Axiaci, funded by the Robert Wood Johnson Foundation, reviewed all 300 carriers offering 2026 individual and family Marketplace plans and found that only 26 carriers cover GLP-1s for obesity, concentrated in nine states: California, North Dakota, New York, Vermont, Pennsylvania, West Virginia, Rhode Island, Delaware and Georgia. In California and North Dakota, all carriers offer plans that cover them. All but four carriers restrict coverage to people with a BMI of 40 or above. Enrollment with any such coverage fell from 3.6 million in 2024 to 2.8 million in 2026 [6][7].

Earlier KFF work using 2024 federal plan data found Wegovy on about 1 percent of Marketplace prescription drug formularies, compared with Ozempic on 82 percent [8] — the clearest illustration anywhere that the barrier is the indication, not the molecule.

North Dakota is the exception that proves the rule. After legislation to require Medicaid coverage failed, the state instead amended its essential health benefit benchmark plan, with CMS approval in 2023, to require individual and small-group plans to cover GLP-1 and GIP drugs as therapy for the prevention of diabetes and the treatment of insulin resistance, metabolic syndrome or morbid obesity [9][11]. That “morbid obesity” wording is why carriers there commonly apply a BMI 40 threshold.

How do I check my own state?

1. Search for “[your state] Medicaid preferred drug list” or “[your state] Medicaid pharmacy prior authorization criteria.” Every state publishes these.
2. Look for the anti-obesity, weight-management or GLP-1 section.
3. Check the document date. State rules can change mid-year with a budget.
4. If you are in a Medicaid managed care plan rather than fee-for-service, check the plan’s own drug list too — managed care plans can differ from the state fee-for-service list.
5. Ask your prescriber’s office whether another approved indication applies to you.
6. If you are denied, ask about the state’s Medicaid appeal and fair hearing process; the denial notice must tell you how to request one.

The short version

Diabetes, cardiovascular risk reduction and obstructive sleep apnea coverage is required everywhere. Obesity coverage is optional: 16 states in October 2025, 13 in January 2026, and 12 from July 2026 once Massachusetts dropped out. Where it exists, prior authorization almost always applies. Children under 21 have stronger rights through EPSDT than adults do. And the ACA Marketplace is not a workaround — for 2026 it is narrower than Medicaid in most states.

Sources

1. KFF, Medicaid Coverage of and Spending on GLP-1s, January 16, 2026. https://www.kff.org/medicaid/medicaid-coverage-of-and-spending-on-glp-1s
2. Stateline, More states consider dropping GLP-1 weight loss drugs from Medicaid, April 30, 2026. https://stateline.org/2026/04/30/more-states-consider-dropping-glp-1-weight-loss-drugs-from-medicaid
3. North Carolina DHHS, NC Medicaid to Change Coverage for GLP-1 Weight Management Medications, September 5, 2025. https://medicaid.ncdhhs.gov/blog/2025/09/05/nc-medicaid-change-coverage-glp-1-weight-management-medications
4. National Conference of State Legislatures, GLP-1s: Cost, Coverage and State Policy Trends. https://www.ncsl.org/health/glp-1s-cost-coverage-state-policy-trends
5. KFF, What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid. https://www.kff.org/medicare/what-to-know-about-the-balance-model-for-glp-1s-in-medicare-and-medicaid
6. Leverage|Axiaci, Obesity Drug Marketplace Coverage Shrinks as Barriers Expand. https://axiacione.com/in-the-news/obesity-drug-marketplace-coverage-shrinks-as-barriers-expand
7. Becker’s Payer Issues, GLP-1 coverage under ACA plans continues to decline: 6 notes. https://www.beckerspayer.com/payer/aca/glp-1-coverage-under-aca-plans-continues-to-decline-6-notes
8. KFF, Costly GLP-1 Drugs are Rarely Covered for Weight Loss by Marketplace Plans. https://www.kff.org/affordable-care-act/costly-glp-1-drugs-are-rarely-covered-for-weight-loss-by-marketplace-plans
9. North Dakota Insurance Department, Feds approve new benefits for North Dakota ACA plans. https://www.insurance.nd.gov/news/feds-approve-new-benefits-north-dakota-aca-plans
10. Medi-Cal Rx, California DHCS, Reminder: Quantity Limit Restrictions for Anti-Obesity Preparations, July 2024. https://medi-calrx.dhcs.ca.gov/cms/medicalrx/static-assets/documents/provider/pharmacy-news/2024.07_A_Reminder_Quantity_Limit_Restrictions_Anti-Obesity_Preparations.pdf
11. North Dakota Monitor / Stateline, States retreat from covering drugs for weight loss but not North Dakota, November 30, 2025. https://northdakotamonitor.com/2025/11/30/repub/states-retreat-from-covering-drugs-for-weight-loss
12. MultiState, GLP-1 Weight Loss Drugs: Coverage Under Medicaid and Other Health Plans. https://www.multistate.us/insider/2025/3/17/glp-1-weight-loss-drugs-coverage-under-medicaid-and-other-health-plans
13. MassHealth, Pharmacy Facts #271 — MassHealth Changes to Management of Anti-Obesity Medications (corrected), March 12, 2026. https://www.mass.gov/doc/pharmacy-facts-271-march-12-2026-corrected-0/download
14. The Boston Globe, MassHealth drops GLP-1 coverage for obesity Friday, July 2, 2026. https://www.bostonglobe.com/2026/07/02/metro/ozempic-wegovy-masshealth-medicaid-obesity-coverage
15. Public Sector HealthCare Roundtable, Most states decline the federal BALANCE Medicaid GLP-1 model (reported September 2026). https://www.facebook.com/MassRetirees/posts/latest-from-the-public-sector-healthcare-roundtable-most-states-decline-federal-/1515416500629398
16. Medical Daily, BALANCE model Medicaid GLP-1 state participation coverage gap, September 2026. https://www.medicaldaily.com/balance-model-medicaid-glp1-state-participation-coverage-gap-477723
17. healthinsurance.org, Does health insurance cover GLP-1 medications for weight loss? (updated September 2026). https://www.healthinsurance.org/faqs/does-health-insurance-cover-glp-1-medications-for-weight-loss
18. FormBlends, Is Zepbound covered by Medicaid? (Rhode Island October 1, 2026 change). https://formblends.com/articles/cost-access/is-zepbound-covered-by-medicaid